Zoetis (ZTS) Competitors

In the previous week, Zoetis had 16 more articles in the media than Royalty Pharma. MarketBeat recorded 30 mentions for Zoetis and 14 mentions for Royalty Pharma. Zoetis' average media sentiment score of 1.45 beat Royalty Pharma's score of 1.37 indicating that Zoetis is being referred to more favorably in the news media.

Royalty Pharma has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Royalty Pharma presently has a consensus target price of $56.57, indicating a potential downside of 3.18%. Zoetis has a consensus target price of $118.33, indicating a potential upside of 52.94%. Given Zoetis' higher possible upside, analysts clearly believe Zoetis is more favorable than Royalty Pharma.

Zoetis has higher revenue and earnings than Royalty Pharma. Zoetis is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.6%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.7%. Royalty Pharma pays out 63.9% of its earnings in the form of a dividend. Zoetis pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has raised its dividend for 5 consecutive years and Zoetis has raised its dividend for 14 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Royalty Pharma has a net margin of 33.88% compared to Zoetis' net margin of 27.80%. Zoetis' return on equity of 66.85% beat Royalty Pharma's return on equity.

Jazz Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

Jazz Pharmaceuticals currently has a consensus price target of $259.06, indicating a potential upside of 2.45%. Zoetis has a consensus price target of $118.33, indicating a potential upside of 52.94%. Given Zoetis' higher possible upside, analysts clearly believe Zoetis is more favorable than Jazz Pharmaceuticals.

Zoetis has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Zoetis has a net margin of 27.80% compared to Jazz Pharmaceuticals' net margin of 0.66%. Zoetis' return on equity of 66.85% beat Jazz Pharmaceuticals' return on equity.

In the previous week, Zoetis had 10 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 30 mentions for Zoetis and 20 mentions for Jazz Pharmaceuticals. Zoetis' average media sentiment score of 1.45 beat Jazz Pharmaceuticals' score of 1.40 indicating that Zoetis is being referred to more favorably in the news media.

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Corcept Therapeutics had 15 more articles in the media than Zoetis. MarketBeat recorded 45 mentions for Corcept Therapeutics and 30 mentions for Zoetis. Zoetis' average media sentiment score of 1.45 beat Corcept Therapeutics' score of 0.48 indicating that Zoetis is being referred to more favorably in the media.

Zoetis has a net margin of 27.80% compared to Corcept Therapeutics' net margin of 6.52%. Zoetis' return on equity of 66.85% beat Corcept Therapeutics' return on equity.

Zoetis has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

Zoetis presently has a consensus price target of $118.33, indicating a potential upside of 52.94%. Corcept Therapeutics has a consensus price target of $119.17, indicating a potential upside of 4.08%. Given Zoetis' higher possible upside, analysts plainly believe Zoetis is more favorable than Corcept Therapeutics.

92.8% of Zoetis shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 0.2% of Zoetis shares are held by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Zoetis has higher revenue and earnings than Corcept Therapeutics. Zoetis is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Supernus Pharmaceuticals presently has a consensus target price of $62.83, indicating a potential upside of 40.79%. Zoetis has a consensus target price of $118.33, indicating a potential upside of 52.94%. Given Zoetis' higher probable upside, analysts plainly believe Zoetis is more favorable than Supernus Pharmaceuticals.

92.8% of Zoetis shares are held by institutional investors. 8.5% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Supernus Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

In the previous week, Zoetis had 22 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 30 mentions for Zoetis and 8 mentions for Supernus Pharmaceuticals. Zoetis' average media sentiment score of 1.45 beat Supernus Pharmaceuticals' score of 1.03 indicating that Zoetis is being referred to more favorably in the news media.

Zoetis has a net margin of 27.80% compared to Supernus Pharmaceuticals' net margin of -3.74%. Zoetis' return on equity of 66.85% beat Supernus Pharmaceuticals' return on equity.

Zoetis has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.